Tavotek Biotherapeutics’ Post

With 14 approvals and counting (11 for the treatment of cancer and 3 for non-oncology indications), bispecific antibodies are revolutionising cancer and other treatments by targeting multiple pathways and engaging diverse immune cells. From dual modulators to next-gen cytokine mimetics, explore the latest advancements shaping the future of precision medicine in the article below.

An awesome read about the history of immunotherapies, the story of coming of age and to market and the successes we've seen so far. There are lots of reasons to be hopeful about cancer therapeutics evolving to the next level, and immunotherapeutic drugs are one of our best success stories. I think that personalized cancer vaccines hold the most potential moving forward, with mRNA vaccines being the platform I believe most likely to see the next "big thing". https://lnkd.in/gkDsV53z

Open Exploration | Exploration of Targeted Anti-tumor Therapy ⏰ It's time to Explore the mysteries of #TumorTherapy with us! 💕 Tips! Welcome to your submission (Indexed in #PubMed #Scopus and #GoogleScholar with no #APCs) 📚 New online #Review sharing! Happy reading! 🎬 Addressing the unmet need in #NSCLC progression with advances in second-line therapeutics 📝 Authors: Robert Hsu* et al. 🎯 This review evaluates current and emerging second-line therapeutic options for advanced or metastatic NSCLC, focusing on their efficacy and potential to improve patient outcomes. 🏃♂️ Welcome to read, forward, and share the article! https://lnkd.in/gxpfcik8 📚 This article belongs to the special issue Immunotherapy Strategies for Non-small Cell Lung Cancer   Non-small cell lung cancer (#NSCLC), antibody-drug conjugates (#ADCs), #SecondLineTherapy, #immunotherapy, #CancerProgression

Dive into the cutting-edge research on #TumorTherapy 🔬 with our latest article! 🚀 No #APCs, indexed in #PubMed, #Scopus, and #GoogleScholar. 📈 Check out the insights on #NSCLC and #SecondLineTherapy by Robert Hsu et al. 👨⚕️ Read, share, and stay ahead in the field! 🌐 #Immunotherapy #CancerProgression #ADCs

Experts discussed the challenges and experiences in establishing standard operating procedures for implementing bispecific antibodies, a potent therapeutic class that serves as an alternative or complement to CAR T-cell therapies in cancer treatment. https://lnkd.in/eUanRjre

ImmunityBio, Inc. declares the FDA's approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist designed for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer. This innovative immunotherapy not only stimulates the proliferation and activation of the patient’s own NK cells and CD8+ killer T cells but also initiates the activation of CD4+ T helper cells, thus enhancing the proliferation of memory killer T cells. Novel immunotherapy stands as a focal point of discussion for the upcoming 2024 Annual Conference of our society, set to convene in Cambridge, MA, USA on Saturday, May 11, 2024. We extend a warm invitation for you to join us in engaging dialogues. Registration for the conference is now open via the following link. https://lnkd.in/ecmFPA4v   #antibodydiscovery #antibodydrugconjugates #oncology #annualmeeting #annualconference #antibodies #mab #mabs #immunotherapy https://lnkd.in/gqPVRV4d).

As of the end of 2023, 14 BsAbs have received approval, predominantly for cancer treatment, demonstrating their potential in addressing various malignancies through different mechanisms, such as dual signaling pathway modulation, targeted receptor activation, and immune cell engagement. These antibodies come in various formats and target a broad spectrum of antigens, reflecting their versatility and potential for personalized cancer therapy. The development of bsAbs is guided by the biology of cancer, requiring careful selection of targets, epitopes, and antibody formats to optimize their efficacy and safety. #cancer #oncology #antibody https://lnkd.in/dJEk_RNC

💡 Compelling Article on Antibody Drug Conjugates (ADCs) 💡 Oncologists are increasingly excited about Antibody Drug Conjugates (ADCs), a groundbreaking advancement in cancer treatment. ADCs allow for the use of more potent chemotherapy agents by attaching the drug to an antibody, delivering powerful cancer-fighting medicines directly into tumour cells. This innovative approach significantly reduces side effects and improves treatment success rates. The precision of ADCs offers new hope for more effective and targeted cancer therapies. Find out more about this exciting area of research: https://lnkd.in/egQFNMea #ADC #Therapy #CancerResearch #CancerTherapeutics

🎉 Excited to share that our manuscript, “Assessment of Mirvetuximab Soravtansine Immunogenicity in Patients with Folate Receptor Alpha-Positive Ovarian Cancer,” has been published in Bioanalysis!

ASH 2024: Bispecific Antibodies Face Key Challenges for Implementation in Community Cancer Centers: Donald Moore discusses some of the obstacles that bispecific antibodies have faced in community cancer centers, including misconceptions coupled with a prevalent toxicity profile. #finance #pharmacy #lifesciences